Top-N Research Lists: Ranked PubMed Studies on GLP-1s
Each list ranks 10 peer-reviewed studies by clinical impact and evidence weight, with PMIDs, ClinicalTrials.gov links, and short editorial summaries. Every PMID was live-verified via PubMed esummary on the listed verification date.
Looking for full-length deep-dives instead? Browse our long-form research articles.
Top 10 PubMed Studies on Semaglutide for Weight Loss (2026)
10 ranked papers · semaglutide · wegovy · ozempic
Ten peer-reviewed semaglutide weight-loss studies anchored to the STEP program (STEP-1 to STEP-8, STEP-TEENS, STEP-HFpEF), the SELECT cardiovascular outcomes trial, and OASIS-1 high-dose oral. Each entry includes the PMID, trial design, primary endpoint, and editorial summary.
Last verified 2026-05-27
Top 10 PubMed Studies on Tirzepatide for Weight Loss (2026)
10 ranked papers · tirzepatide · zepbound · mounjaro
Ten peer-reviewed tirzepatide weight-loss studies anchored to the SURMOUNT program (SURMOUNT-1 through SURMOUNT-5, plus SURMOUNT-CN and SURMOUNT-OSA), the SYNERGY-NASH liver-fibrosis trial, the SUMMIT HFpEF trial, and the SURPASS-2 head-to-head against semaglutide. Each entry includes the PMID, trial design, primary endpoint, and editorial summary.
Last verified 2026-05-27
Top 10 PubMed Studies on GLP-1 Cardiovascular Outcomes (2026)
10 ranked papers · GLP-1 · cardiovascular · MACE
Ten landmark cardiovascular outcomes trials that established GLP-1 receptor agonists as cardioprotective drugs beyond glycemic control. Covers MACE reduction in type 2 diabetes (LEADER, SUSTAIN-6, REWIND, HARMONY OUTCOMES, AMPLITUDE-O, PIONEER 6), the SELECT paradigm-shift in obesity without diabetes, kidney outcomes in FLOW, heart failure in STEP-HFpEF, and the foundational neutral ELIXA post-ACS trial. Each entry includes the PMID, NCT, primary endpoint, and editorial summary.
Last verified 2026-05-27